Company Filing History:
Years Active: 2024
Title: Sreekala Mandiyan: Innovating Cancer Treatment through Anti-MET Antibodies
Introduction
Sreekala Mandiyan, based in Bloomfield, NJ, is an accomplished inventor making significant strides in the field of cancer research. With a strong focus on therapeutic innovations, her work centers on developing antibodies that target specific receptors involved in cancer progression.
Latest Patents
Sreekala holds a notable patent for "Anti-MET antibodies and methods of use thereof." This patent entails compositions and methods involving antibodies that specifically bind to the MET receptor tyrosine kinase. The innovative approach outlined in her patent aims to modulate the expression and activity of MET, paving the way for new strategies in managing, treating, or preventing disorders, including cancer. Included in her patent are monoclonal antibodies or antigen-binding fragments that target the Sema/PSI domain of human MET. Additionally, the patent describes methods and kits for administering these antibodies effectively, demonstrating a potential breakthrough in cancer therapeutics.
Career Highlights
Sreekala is currently affiliated with Celldex Therapeutics Limited, where she contributes her expertise to advancing cancer treatment methodologies. Her background and dedication to research make her a valuable asset in the biopharmaceutical landscape.
Collaborations
Throughout her career, Sreekala has collaborated with esteemed colleagues, including Yan Yang and Brett Robinson. These partnerships foster an environment of innovation and knowledge sharing, further enhancing the impact of their collective research efforts.
Conclusion
Sreekala Mandiyan's contributions to the field of cancer treatment through her patent on Anti-MET antibodies exemplify the transformative potential of targeted therapies. Her work is paving the way for advancements in medical science, offering hope for better management and treatment options for cancer patients. As she continues to innovate, Sreekala stands as a key player in the ongoing battle against this devastating disease.